Esperion Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−11.18%
vs ±15.3% implied · ×0.73
shaded = implied · ▲▼ = realized
No thesis.
Esperion Therapeutics, Inc.
3.20
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Glazer CapitalGlazer Capital | $70.8M | 10.85% | new | |
| 2 | BlackRockBlackRockindex-like | $69.9M | 10.71% | +23.95% | |
| 3 | Vanguard Capital ManagementVanguardindex-like | $36.1M | 5.53% | +9.52% | |
| 4 | Trium CapitalTrium Capital | $35.3M | 5.40% | new | |
| 5 | Goldman Sachs GroupGoldman Sachs | $32.8M | 5.02% | +330.65% | |
| 6 | State StreetState Streetindex-like | $23.0M | 3.52% | +3.12% | |
| 7 | Two Sigma InvestmentsTwo Sigma | $22.5M | 3.45% | −24.65% | |
| 8 | Geode Capital ManagementGeodeindex-like | $21.0M | 3.21% | +11.32% | |
| 9 | CNH PartnersCNH Partners | $19.1M | 2.93% | new | |
| 10 | Oddo BHF Asset Management SASOddo BHF Asset Management SAS | $15.8M | 2.42% | new | |
| 11 | Balyasny Asset ManagementBalyasny | $14.7M | 2.25% | new | |
| 12 | FMRFMR | $14.6M | 2.23% | +1131.76% | |
| 13 | Beryl Capital ManagementBeryl | $14.0M | 2.14% | new | |
| 14 | PenderFund Capital ManagementPenderFund | $12.3M | 1.88% | −0.19% | |
| 15 | UBS GroupUBS | $12.1M | 1.86% | −10.61% | |
| 16 | AlliancebernsteinAlliancebernstein | $11.3M | 1.74% | +1270.61% | |
| 17 | PSquared Asset ManagementPSquared | $10.4M | 1.60% | new | |
| 18 | Highland Capital Management Fund AdvisorsHighland | $9.3M | 1.43% | new | |
| 19 | Gabelli FundsGabelli Funds | $9.1M | 1.39% | new | |
| 20 | TIG AdvisorsTIG | $8.2M | 1.25% | new | |
| 21 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $7.8M | 1.20% | −30.03% | |
| 22 | Northern TrustNorthern Trustindex-like | $7.3M | 1.12% | +10.35% | |
| 23 | Gabelli SecuritiesGabelli Securities | $7.3M | 1.12% | new | |
| 24 | Millennium ManagementMillennium | $7.0M | 1.08% | +268.29% | |
| 25 | Sagefield CapitalSagefield Capital | $6.9M | 1.06% | new |
190 managers report $652.9M of Esperion Therapeutics on form 13F for the quarter ended Jun 30 '26. 30 of them hold 80% of it; Glazer Capital is largest at 10.85%.
Fund move
Fund move
Expected move
No implied move.
No implied move.
No implied move.
Linked news